BOSTON--(BUSINESS WIRE)--Allied Minds, Inc., an early-stage technology capital investment firm focused on commercializing technologies from leading U.S. Universities and National Labs, today announced the appointment of Omar Amirana, M.D. as Managing Director, Life Sciences. Dr. Amirana is a recognized life sciences leader and investor with more than twenty years of experience in the life sciences industry.
“Omar brings to Allied Minds a tremendous wealth of investing and product commercialization experience,” said Chris Silva, Chief Executive of Allied Minds. “His ability to identify investment opportunities and to work with inventors while building high quality teams in order to commercialize and launch new technologies worldwide is going to help us grow significantly. His technical, clinical, marketing, and business development experience as a leader, entrepreneur and venture capitalist will enhance our team and portfolio significantly.”
Dr. Amirana spent the past six years as a Partner at Oxford Bioscience Partners, a Boston based venture capital firm with ~$1B under management, where he focused on medical device and technology investing. He has helped grow and exit several venture backed medical device companies as a senior executive or board member. He has served on the boards of development and revenue stage companies such as Coherex, SmartPill, Flowmedica, and NFocus Neuromedical. He will retain board seats at Cardiofocus and Cambridge Endoscopic Devices. His previous experience includes Vice President of Business Development at St. Jude Medical, a medical device company with over $5B in revenue, where he also ran a 20 person R&D team. He was Vice President of Marketing at MedicaLogic, a leader in electronic medical records. In addition to being a cofounder of Cardima, an electrophysiology catheter spinout of Target Therapeutics, he has held senior executive positions in R&D, Sales, Marketing, and Business Development and as CEO at several life science companies in Silicon Valley.
“Allied Minds represents a new investment model for early stage investing in today’s economy. Fortified with capital from institutional investors to grow startup companies from the ground floor, Allied Minds is well equipped to enhance shareholder value in a capital efficient and operationally focused model while pioneering ground breaking technologies,” said Dr. Amirana. “It is exciting to be more operationally engaged again while continuing to invest. I am looking forward to working with the team and to spurring innovation within the Allied Minds model.”
Dr. Amirana received a B.S., Mechanical Engineering from Tufts University and a Medical Degree from Eastern Virginia Medical School.
About Allied Minds
Allied Minds is a private equity-funded innovation company with offices in Boston and Los Angeles. The Company creates startup businesses based on early-stage technology developed at renowned U.S. universities and national labs, and serves as a holding company that supports these businesses with capital, management and shared services. Allied Minds is the premier firm to utilize this novel and fully-integrated approach to technology investing. The Company’s subsidiary investments span multiple business sectors and offer an attractive risk-return profile, a deliverable timeline and potential products that will be groundbreaking in their respective fields. These subsidiaries include BA Logix, Biotectix, Cephalogics, CryoXtract, Illumasonix, ProGDerm, Precision Biopsy, Purtein, RF Biocidics, SaltCheck, SciFluor Life Sciences, SiEnergy Systems, SoundCure and Spin Transfer Technologies. For more information, please visit www.alliedminds.com.